Tachycardia | Pathophysiology of Orthostatic Intolerance
Tachycardia research study
What is the primary objective of this study?
The purpose of this study is to describe the mechanism of orthostatic intolerance, relying on cardiovascular physiological studies. The syndrome is of undetermined etiology, but the syndrome causes impairment of a number of young adults, females more than males, with symptoms of tachycardia, fatigue, lightheadedness, palpitations, blurred vision, chest discomfort, difficulty concentrating, and dizziness with the upright posture. It is believed that many different pathophysiological processes can give rise to this disorder.
Who is eligible to participate?
Inclusion Criteria: - Orthostatic intolerance Exclusion Criteria: - Inability or unwillingness to give informed consent
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Postural Orthostatic Tachycardia Syndrome
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Radiation:DAXOR131-I-Human Serum Albumin Blood Volume Assessment Kit
Procedure:QSweatQuantitative Sweat Testing
Drug:Intrinsic Heart RateAtropine 0.04 mg/kg IV in divided doses Propranolol 0.2 mg/kg IV in divided doses
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
PatientsPatients with orthostatic intolerance
Healthy Control SubjectsHealthy subjects to determine "normal" response
Start Date: December 1996
Completed Date: December 2019
Primary Outcome: Physiological abnormalities in orthostatic intolerance
Secondary Outcome: blood volume
Study sponsors, principal investigator, and references
Principal Investigator: David Robertson, MD
Lead Sponsor: Satish R. Raj
Collaborator: National Institutes of Health (NIH)